FBW7 mutations have a broad functional role in determining therapeutic responses of cancer cells 8, and can modulate responses to γ secretase inhibitors in leukemia cells 39, to histone deacetylase inhibitors in squamous tumor cells 40, and to antimitotic drugs in CRC cells 41. This evidence concerns the gene FBXW7 and colorectal carcinoma.